Mutation testing - PDFSEARCH.IO - Document Search Engine

Mutation testing
Results: 207

#	Item
41	Public Summary Document Application No[removed]Cetuximab and KRAS mutation testing under MBS 73330 Applicant: Merck Serono Australia Pty Ltd Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-12-16 20:01:29 Bristol-Myers Squibb Cetuximab KRAS Panitumumab Oncogenes Gastrointestinal cancer Ras subfamily Colorectal cancer HRAS Medicine Biology Oncology
42	Public Summary Document Application No. 1161 – Assessment of EGFR mutation testing for the use of gefitinib in locally advanced or metastatic nonsquamous NSCLC Sponsor/Applicant/s: AstraZeneca Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:57 Amines Quinazolines Lung cancer Organofluorides Biotechnology Gefitinib Epidermal growth factor receptor Non-small-cell lung carcinoma Biomarker Chemistry Medicine Organic chemistry
43	Chromosome Microarray (CMA) Testing in Children and Adults Fact Sheet 6A There is a CMA Testing Guide for doctors and patients available at www.genetics.edu.au As part of an investigation into a developmental or health c Add to Reading List Source URL: www.genetics.edu.au Language: English Genetic testing Mutation Gene DNA Human genome Comparative genomic hybridization Biology Genetics Chromosome
44	Faulty genes and cancer Our bodies are made up of billions of cells. These cells contain a copy of the genetic plan for our growth, development and health. This genetic plan comes in the form of genes which we inherit fr Add to Reading List Source URL: www.genetics.edu.au Language: English Ribbon symbolism Gynaecological cancer Ovarian cancer Cancer Breast cancer Genetic testing Colorectal cancer BRCA mutation Prostate cancer Medicine Oncology Gastrointestinal cancer
45	1293 Consultation Decision Analytic Protocol (DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for afatinib treatment in patients with stage IIIB or stage IV Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:25 Quinazolines Tyrosine kinase receptors Organofluorides Amines Organochlorides Gefitinib Erlotinib Epidermal growth factor receptor Afatinib Chemistry Organic chemistry Medicine
46	Public Summary Document Application No. 1173 – Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for erlotinib treatment as a first line therapy in patients with locally advanced or metastat Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:40 Amines Quinazolines Lung cancer Organofluorides Alkynes Gefitinib Erlotinib Epidermal growth factor receptor Non-small-cell lung carcinoma Chemistry Medicine Organic chemistry
47	1293 Final Decision Analytic Protocol (DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for afatinib treatment in patients with stage IIIB or stage IV non-sma Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:26 Quinazolines Organofluorides Amines Organochlorides Lung cancer Gefitinib Erlotinib Epidermal growth factor receptor Afatinib Chemistry Organic chemistry Medicine
48	Public Summary Document Application No. 1173 – Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for erlotinib treatment as a first line therapy in patients with locally advanced or metastat Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:43 Amines Quinazolines Lung cancer Organofluorides Alkynes Gefitinib Erlotinib Epidermal growth factor receptor Non-small-cell lung carcinoma Chemistry Medicine Organic chemistry
49	. Feedback Survey Application[removed]Germline BRCA mutation testing to determine eligibility for olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer (including fallopian tube or prim Add to Reading List Source URL: www.cancervoicesaustralia.org Language: English - Date: 2014-11-17 19:20:13 Breast cancer Gynaecological cancer BRCA mutation Mutation Olaparib Ovarian cancer Primary peritoneal carcinoma Cancer BRCA2 Medicine Oncology Ribbon symbolism
50	MSAC Application 1173: Final Decision Analytical Protocol (DAP) to guide the assessment of Epidermal Growth Factor Receptor (EGFR) gene mutation testing for eligibility for erlotinib treatment as a first-line therapy in Add to Reading List Source URL: www.msac.gov.au Language: English - Date: 2014-11-06 23:49:40 Lung cancer Amines Quinazolines Organofluorides Alkynes Gefitinib Erlotinib Epidermal growth factor receptor Non-small-cell lung carcinoma Medicine Chemistry Oncology

UPDATE